The present study confirms and extends our previously reported open‐label, prospective evaluation of the effectiveness of icatibant in the treatment of eight patients with HAE‐nC1 INH, and seven patients with HAE type I 21. This evidence concerns the gene COL18A1 and hereditary angioedema.